On September 25, 2019 Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that the United States Patent and Trademark Office has issued a patent with claims related to the Company’s proprietary liposomal delivery and antisense technology, DNAbilize, including its use in the treatment of cancers, autoimmune diseases and infectious diseases (Press release, Bio-Path Holdings, SEP 25, 2019, View Source [SID1234539772]). This is the second U.S. patent issued for the Company’s platform technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new patent, United States Patent No. 10,335,428 (based on Application No. 15/657,083), titled "P-Ethoxy Nucleic Acids for Liposomal Formulation," which issued July 2, 2019, provides additional claims for the broad protection previously granted in Patent No. US 9,744,187 (issued August 29, 2017) for application of the DNAbilize technology in the treatment of a variety of cancers, as well as autoimmune and infectious diseases. DNAbilize is a proprietary liposomal nanoparticle delivery and antisense technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion.
Bio-Path’s platform technology patents allow the Company to develop new drug product candidates using its proprietary DNAbilize technology. As new drug product candidates are developed using DNAbilize technology, new patent applications can be filed for the specific drug products incorporating DNAbilize technology.
Applying the DNAbilize technology to a protein target can result in a specific drug product for which a new DNAbilize drug product patent application can be filed. The Company anticipates that the number of DNAbilize drug product candidates will increase significantly in the coming years.
The Company believes its patented platform technology provides a powerful template with the capability to produce a large portfolio of patented drug products. The Company currently has two issued platform technology patents for DNAbilize and five pending patent applications for specific DNAbilize drug product candidates. Each of the issued technology platform patents has a life of twenty years from filing, and any issued patents for specific DNAbilize drug products will also be protected for twenty years from filing.
Consequently, the Company expects its expanding intellectual property estate for DNAbilize to be a source of both exciting breakthroughs in cancer therapy and to be an engine for out-licensing opportunities across a broad spectrum of cancer indications with currently unmet medical needs.
"Our strategy is to leverage the value of our patented DNAbilize technology by focusing on our mission to develop systemic DNAbilize treatments for hard-to-treat diseases. In doing so, we believe we can develop multiple drug products that can enhance shareholder value through partnering or licensing at various stages of drug product development. This will allow Bio-Path to focus on the front-end of the development process, while partnering out development through later stages of clinical development," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.